COCRYSTAL PHARMA – COCP NASDAQ
These shares have soared recently breaking our of a solid base formation, quadrupling in value as the SHORTS SCRAMBLE. With a 52 week high of $3.24 these shares are ready to rumble .
Minor resistance exists at the $2.20 – $2.50 levels, next resistance $5.00 .Biotech and high volatility go hand in hand and we expect these shares to move much higher as the Coronavirus sweeps through the world and the shorts see the error of their ways.
These shares have been under accumulation by major institutional investors . We urge all serious investors to place these shares on their BUY LIST
Cocrystal Pharma (NASDAQ:COCP) +63.1% pre-market after nearly tripling yesterday following news it entered into a license agreement with Kansas State University Research Foundation to further develop proprietary antiviral compounds for the treatment of norovirus and coronavirus.
Under the deal terms, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain antiviral compounds for humans covered by KSURF’s patents.
Cocrystal says it will pursue research and development of theses antiviral compounds, including pre-clinical and clinical development, and the license will significantly advance its antiviral programs by providing potent compounds for further development.
Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds
COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into a license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections.
Under the terms of the agreement, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain antiviral compounds for humans covered by KSURF’s patents. Cocrystal intends to pursue research and development of theses antiviral compounds, including preclinical and clinical development. This license advances the Company’s antiviral programs significantly by providing potent compounds for further development.
“We are incredibly pleased to contract with the Kansas State University Research Foundation as we seek to develop safe and effective antiviral therapies for these viruses. This license agreement opens several development opportunities for us to expand the broad utility of our platform to address significant viruses for which there are unmet medical needs, particularly the COVID-19 coronavirus and norovirus,” commented Dr. Sam Lee, President of Cocrystal. “There is an urgent demand to address the public health threat that the coronavirus continues to present, and we believe that our proprietary drug discovery platform has the capability to do just that. We intend to seek opportunities for collaborations as we advance these programs.”
Cocrystal’s technology generates a 3-D structure of inhibitor complexes at near-atomic resolution providing the Company with the ability to identify novel binding sites, which allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. By utilizing this technology, Cocrystal is able to develop compounds that specifically target enzymes that are important to viral replication. The Company is currently leveraging its unique structure-based technologies to develop antiviral drugs for hepatitis C, influenza and norovirus.
About Coronavirus Disease 2019 (COVID-19)
The Centers for Disease Control and Prevention (CDC) is closely monitoring an outbreak of respiratory illness caused by this new coronavirus (COVID-19) first identified in Wuhan, Hubei Province, China. Initially many of the patients in the outbreak in Wuhan, China reportedly had some link to a large seafood and animal market, suggesting animal-to-person spread. However, a growing number of patients reportedly have not had exposure to animal markets, indicating person-to-person spread is occurring. At this time, it’s unclear how easily or sustainably this virus is spreading between people. Summary updates are available on CDC’s web page: Coronavirus Disease 2019 (COVID-19).
About Norovirus Disease
There are no drugs approved for Norovirus infections. In the US alone, there are between 19-21 million Norovirus cases every year. This highly contagious virus is responsible for cruise ships returning to shore, and outbreaks of gastroenteritis occurring in confined living quarters, hospitals, and retirement centers. The global economic burden of Norovirus is greater than $60 billion per year. There are three distinct markets we intend to target: acute infection, chronic infection, and prophylaxis. Additional information is available at World Economic Forum titled “What is the economic impact of norovirus infections,” 2016; and CDC titled “Norovirus Disease in the United States,” 2013.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.